WYPH
WayPoint Biomedical Holdings, Inc., operating through its wholly-owned subsidiary, WayPoint Biomedical, Inc., specializes in the development and market introduction of various diagnostic instruments and testing kits. These products are designed for monitoring human health, assessing fitness levels, and analyzing environmental factors. Among its notable health-related offerings is the "Drink Detective," a test specifically engineered to identify date rape drugs like Ketamine, GHB, and Benzodiazepines in beverages. Additionally, the company provides "Health Essist" tests for the detection of substances such as cocaine and marijuana. Beyond health applications, WayPoint Biomedical also develops and sells advanced detection kits for security purposes. This includes technologies aimed at identifying potential explosive devices, biowarfare or bioterrorism agents, and weapons of mass destruction. A key product in this category is the "Frontline Explosive Test Kit," tailored for detecting explosive residues. The company's diverse portfolio serves multiple sectors: consumer-facing over-the-counter diagnostic self-testing, professional point-of-care diagnostic providers, and critical homeland security and defense initiatives. WayPoint Biomedical Holdings was established in 2004 and is headquartered in Huntington Beach, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 0.00 | $0 | — |
| 2022 Q1 | -0.00 | $0 | — |